Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.
Mannatech pays an annual dividend of $2.00 per share and has a dividend yield of 10.4%. Rock Creek Pharmaceuticals does not pay a dividend. Mannatech has raised its dividend for 2 consecutive years.
Valuation and Earnings
This table compares Rock Creek Pharmaceuticals and Mannatech’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Rock Creek Pharmaceuticals||N/A||N/A||N/A||N/A||N/A|
|Mannatech||$176.70 million||0.26||-$1.78 million||N/A||N/A|
Rock Creek Pharmaceuticals has higher earnings, but lower revenue than Mannatech.
This is a breakdown of recent recommendations and price targets for Rock Creek Pharmaceuticals and Mannatech, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rock Creek Pharmaceuticals||0||0||0||0||N/A|
This table compares Rock Creek Pharmaceuticals and Mannatech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rock Creek Pharmaceuticals||N/A||N/A||N/A|
Insider and Institutional Ownership
16.0% of Mannatech shares are owned by institutional investors. 0.9% of Rock Creek Pharmaceuticals shares are owned by company insiders. Comparatively, 24.7% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Rock Creek Pharmaceuticals has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500.
Mannatech beats Rock Creek Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
Rock Creek Pharmaceuticals Company Profile
Rock Creek Pharmaceuticals, Inc., a pharmaceutical development company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its lead compound is Anatabine citrate, a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids, and non-steroidal anti-inflammatories. The company was formerly known as Star Scientific, Inc. and changed its name to Rock Creek Pharmaceuticals, Inc. in June 2014. Rock Creek Pharmaceuticals, Inc. is headquartered in Sarasota, Florida. On September 27, 2016, Rock Creek Pharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware.
Mannatech Company Profile
Mannatech, Incorporated provides wellness solutions. The company develops, markets, and sells nutritional supplements, topical, skin care and anti-aging products, and weight-management products. It markets its products through network marketing channels in the Americas, Europe/the Middle East/Africa, and the Asia/Pacific. The company was founded in 1993 and is headquartered in Coppell, Texas.
Receive News & Ratings for Rock Creek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rock Creek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.